Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world claims analysis data at the ISPOR 2026 conference, revealing the significant clinical and economic burden of fibromyalgia in U.S. adults. The findings highlight high rates of comorbidities, extensive healthcare resource utilization, and widespread reliance on multimodal treatment approaches, emphasizing the unmet need for more effective long-term options.
The retrospective analysis examined more than 261,000 adult fibromyalgia patients and found that over 93% had at least one fibromyalgia-related comorbidity. Insured patients faced substantial annual healthcare costs, driven primarily by inpatient services. These data underscore the challenges faced by patients and the healthcare system, as fibromyalgia remains a condition with limited treatment options.
Tonix is advancing its planned commercial launch of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure also supports marketed products for acute migraine, including Zembrace SymTouch and Tosymra. Tonix is also exploring TONMYA’s potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
Beyond fibromyalgia, Tonix’s CNS pipeline includes TNX-2900, Phase 2 ready for Prader-Willi syndrome. The company is also advancing immunology programs, such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention.
The full press release is available at https://ibn.fm/yMppz. For the latest news on TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.
